Gene therapy is already used to treat a growing set of inherited disorders, certain blood cancers, and a handful of other specific conditions, but approved uses remain highly specific rather than broadly available across genetic disease in general. The scale of investment behind this progress has been extraordinary: the global gene therapy market was valued at roughly $7 billion in 2022 and is projected by multiple industry analysts to exceed $30 billion by 2030, a growth trajectory reflected directly in the price tags of individual treatments, which now include some of the most expensive single medical interventions in history.
Zolgensma, approved in 2019 for spinal muscular atrophy, launched at $2.1 million per dose. Hemgenix, approved in 2022 for hemophilia B, currently holds the distinction of being the most expensive drug in the world at roughly $3.5 million per one-time treatment. Skysona and Zynteglo followed at $3 million and $2.8 million, respectively, and Lenmeldy, approved in 2024 for metachromatic leukodystrophy, carries a list price of $4.25 million, making it the single most expensive drug ever approved by the FDA at the time of its launch.
These figures are not arbitrary. The term itself covers several distinct therapeutic approaches, and approval status changes often enough that anyone researching a specific condition should verify current information against the FDA’s own records before making decisions. The economics reflect genuinely small patient populations, extraordinarily complex manufacturing processes, and the fact that many of these therapies replace what would otherwise be a lifetime of expensive, ongoing treatment; hemophilia B patients, for example, have historically faced direct medical costs exceeding $600,000 annually for standard factor replacement therapy, with lifetime treatment costs estimated at more than $47 million for patients living into their seventies, a figure that reframes even a $3.5 million one-time gene therapy as a potential long-term cost offset rather than a pure additional expense.
Which Diseases Have FDA-Approved Gene Therapy Options?
| Disease | Therapeutic approach | Approximate list price | Eligibility considerations |
|---|---|---|---|
| Sickle cell disease | Gene editing or gene addition (ex vivo cell modification) | Roughly $2.2 million (Casgevy) | Confirmed diagnosis, specialist evaluation, treatment center availability |
| Transfusion-dependent beta thalassemia | Gene addition (ex vivo cell modification) | Roughly $2.8 million (Zynteglo) | Confirmed diagnosis, transfusion history |
| Spinal muscular atrophy | Gene replacement (in vivo viral vector) | Roughly $2.1 million (Zolgensma) | Typically used in infants and young children under age two |
| Cerebral adrenoleukodystrophy | Gene addition (ex vivo cell modification) | Roughly $3 million (Skysona) | Early diagnosis, specific genetic confirmation |
| Metachromatic leukodystrophy | Gene addition (ex vivo cell modification) | Roughly $4.25 million (Lenmeldy) | Early-stage disease, genetic confirmation |
| Inherited retinal disease (RPE65-associated) | Gene replacement (in vivo viral vector) | Roughly $425,000 per eye (Luxturna) | Confirmed biallelic RPE65 mutation, viable retinal cells |
| Hemophilia A | Gene replacement (in vivo viral vector) | Multi-million dollar range (Roctavian) | Specific factor levels, absence of certain antibodies |
| Hemophilia B | Gene replacement (in vivo viral vector) | Roughly $3.5 million (Hemgenix) | Specific factor levels, liver function criteria |
| Duchenne muscular dystrophy | Gene therapy delivering a micro-dystrophin gene | Multi-million dollar range (Elevidys) | Specific age range, ambulatory status considerations |
| Severe leukocyte adhesion deficiency-I | Gene addition (ex vivo cell modification) | Multi-million dollar range | Confirmed genetic diagnosis, typically diagnosed in infancy |
| OTOF-associated genetic hearing loss | Gene replacement (in vivo, inner ear delivery) | Not yet fully established | Confirmed OTOF gene mutation |
| Various B-cell blood cancers | CAR T-cell therapy (engineered immune cells) | Roughly $400,000 to $500,000 | Relapsed or refractory disease, specific prior treatment history |
This table reflects therapies with FDA approval as of recent years, but the list continues to expand, and prices shift as new competitors enter specific disease categories. The FDA’s currently maintained database of approved cellular and gene therapy products is the authoritative source for confirming whether a specific therapy remains approved and for what exact indication.
Inherited Blood Disorders
Sickle cell disease, affecting an estimated 100,000 Americans, most of whom are Black, and transfusion-dependent beta thalassemia both have approved gene therapy options that modify a patient’s own blood-forming stem cells outside the body before returning them through a procedure similar to a stem cell transplant. Some approaches add a functional copy of a gene, while others use gene editing technology to change how existing genes are regulated. Casgevy, approved in December 2023, was the first FDA-approved treatment to use CRISPR gene editing technology, a milestone a full decade after CRISPR’s discovery earned its developers a Nobel Prize.
Eligibility for these therapies typically requires specialist evaluation at an accredited treatment center, confirmation of the specific type of sickle cell disease or thalassemia involved, and in many cases a conditioning regimen similar to what is used before a bone marrow transplant. These are intensive treatments, not simple outpatient procedures, and only a few hundred patients had actually received Casgevy or Lyfgenia within the first two years following approval, a modest number relative to the eligible population that reflects the genuine logistical and financial complexity involved in delivering these therapies.
Rare Genetic Disorders
Spinal muscular atrophy, a severe neuromuscular disease affecting roughly 1 in 10,000 live births and historically the leading genetic cause of infant death, was one of the earliest inherited disorders to receive an approved in vivo gene replacement therapy, delivered through a viral vector that supplies a functional copy of the missing gene. Cerebral adrenoleukodystrophy and metachromatic leukodystrophy, both severe neurodegenerative conditions, have approved gene addition therapies that modify blood-forming stem cells to correct an underlying enzyme deficiency.
Aromatic L-amino acid decarboxylase deficiency, an extremely rare inherited disorder affecting neurotransmitter production, also has an approved gene therapy delivered directly to the brain. Having a genetic diagnosis does not automatically mean a gene therapy exists for that specific condition; the list of diseases with approved options, while growing, still represents a small fraction of the more than 7,000 known rare genetic disorders cataloged by organizations like the National Organization for Rare Disorders, the overwhelming majority of which still have no approved targeted treatment of any kind.
Inherited Eye Disorders
An approved gene therapy exists for inherited retinal disease caused by mutations in the RPE65 gene, delivered directly into the eye through a viral vector, at a price of roughly $425,000 per eye. This example illustrates why gene therapy is often tissue-specific: the delivery method and target tissue matter as much as the underlying genetic mechanism, and a therapy effective for one inherited eye condition does not automatically apply to other inherited retinal diseases caused by different genes, even when the resulting vision loss looks clinically similar.
Certain Cancers and Blood Cancers
CAR T-cell therapies represent a form of cellular and gene-based treatment where a patient’s own immune cells are genetically modified outside the body to better recognize and attack cancer cells before being returned to the patient. Several CAR T-cell products are approved for specific relapsed or refractory blood cancers, including certain types of lymphoma, leukemia, and multiple myeloma, with published clinical trial data for some products showing complete remission rates exceeding 50 percent in heavily pretreated patients who had exhausted other standard treatment options, a genuinely remarkable outcome for a patient population with historically very limited remaining options.
This approach differs meaningfully from direct correction of an inherited gene defect. CAR T-cell therapy modifies immune cells to fight an existing cancer rather than correcting a genetic cause of disease, even though both fall under the broader cell and gene therapy category.
Newer Areas of Gene Therapy Expansion
The FDA approved a gene therapy for OTOF-associated genetic hearing loss in 2026, treating a specific inherited cause of deafness through direct inner ear delivery. This approval, along with the approval of a gene therapy for severe leukocyte adhesion deficiency-I the same year, illustrates that the approved-disease list continues to expand into increasingly specific genetic conditions.
Expanding approvals indicate genuine scientific progress, but they should not be read as a guarantee that similar therapies will soon exist for every genetic condition. Each new approval reflects years of research targeting a specific disease mechanism, often a decade or more from initial discovery to FDA approval, and many genetic conditions currently under investigation have not yet reached approval, with hundreds of additional gene therapy candidates currently in various phases of clinical trials worldwide.
Why Gene Therapy Eligibility Is Highly Specific
Eligibility depends on a confirmed genetic diagnosis matching the therapy’s approved indication, molecular confirmation of the specific mutation involved, disease severity and stage, patient age, prior treatments received, organ function, and in some cases the presence or absence of certain antibodies that could interfere with treatment. Manufacturing capacity and treatment center availability add practical constraints beyond the purely medical criteria; some gene therapies can only be manufactured at one or two facilities worldwide, creating genuine bottlenecks even for patients who are otherwise fully eligible.
Two patients with the same general diagnosis can have very different eligibility outcomes depending on these specific factors.
What Gene Therapy Can and Cannot Promise
Some approved gene therapies have shown durable benefit over years of follow-up, but durable benefit is not the same as a guaranteed permanent cure in every case. Long-term outcomes for many newer therapies remain under active study simply because the therapies have not existed long enough to generate decades of follow-up data; Zolgensma, one of the longest-tracked gene therapies, has published follow-up data extending past five years showing sustained benefit in most treated patients, while newer approvals like Lenmeldy and the 2026 hearing loss therapy have only a fraction of that track record so far.
Potential adverse effects vary by therapy and can include immune reactions, infusion-related complications, and in some cases longer-term risks still being characterized through ongoing monitoring.
How Patients Can Check Whether a Gene Therapy Is an Option
Confirming an exact genetic diagnosis through appropriate testing is the necessary first step. From there, asking a specialist whether an FDA-approved therapy exists for that specific indication, understanding the detailed eligibility criteria involved, asking about relevant clinical trials if no approved option exists, and consulting a qualified specialist or accredited treatment center are the practical next steps.
Gene therapy has moved from experimental science into real clinical treatment for a specific and growing set of conditions, transforming a field that produced its first approved product only in the late 1990s into one now supporting a market valued in the tens of billions of dollars and a treatment pipeline with hundreds of additional candidates in active development. Access and eligibility, however, remain tightly defined, shaped as much by manufacturing capacity, insurance negotiation, and treatment center availability as by the underlying science itself.
Confirming a diagnosis and seeking qualified specialist evaluation remains the most reliable path forward, rather than relying on generalized claims found online. As more of these therapies reach the market and competition potentially brings prices down over time, as some industry analysts anticipate happening within specific disease categories once multiple approved options exist, the practical calculus for patients and families weighing these treatments against their lifetime alternatives will likely continue to shift.
This article provides general educational information and is not a substitute for diagnosis, treatment, or specialist medical advice.
FAQ
Q: Which diseases are currently treated with gene therapy?
A: Approved uses include sickle cell disease, beta thalassemia, spinal muscular atrophy, certain inherited retinal and neurodegenerative disorders, hemophilia A and B, Duchenne muscular dystrophy, and several blood cancers treated with CAR T-cell therapy.
Q: Is gene therapy available for all genetic diseases?
A: No. Approved gene therapies exist for a specific and growing list of conditions out of more than 7,000 known rare genetic disorders, and most currently have no approved gene therapy option.
Q: Can gene therapy cure genetic disorders?
A: Some gene therapies have produced durable benefit, with some tracked past five years, but outcomes vary by disease and therapy, and long-term data for many newer treatments is still being collected.
Q: Is gene therapy used for cancer?
A: Yes, particularly through CAR T-cell therapies, which genetically modify a patient’s immune cells to better target certain blood cancers, with some products showing complete remission rates over 50 percent in trial populations.
Q: Which gene therapies are FDA approved?
A: The FDA maintains a current list of approved cellular and gene therapy products, which should be checked directly to confirm the most up-to-date approved indications.
Q: How much do gene therapies cost?
A: Prices vary widely, from around $425,000 per eye for Luxturna to $4.25 million for Lenmeldy, with several other approved therapies priced between $2 million and $3.5 million per treatment.
Q: How do doctors determine gene therapy eligibility?
A: Eligibility depends on confirmed genetic diagnosis, disease severity, age, prior treatments, organ function, and other criteria specific to each approved therapy.
Q: Are gene therapies permanent?
A: Durability varies by therapy. Some have shown lasting benefit over years of follow-up, while long-term outcomes for newer therapies remain under ongoing study.